Amneal Pharmaceuticals, Inc.

AMRXSEC EDGAR

Pharmaceutical PreparationsCIK: 1723128

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$2.4B	$2.2B	$2.1B	$2.0B	$1.6B
Cost of Goods and Services Sold	$1.6B	$1.4B	$1.3B	$1.3B	$1.1B
Gross Profit	$820.6M	$784.7M	$769.0M	$628.4M	$353.0M
Research and Development Expense	$163.9M	$195.7M	$201.8M	$179.9M	$188.0M
Selling, General and Administrative Expense	$429.7M	$399.7M	$365.5M	$326.7M	$289.6M
Operating Expenses	—	—	—	—	—
Operating Income (Loss)	$204.4M	-$94.9M	$152.7M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$3.5B	$3.5B	$3.8B	$3.9B	$4.0B
Assets, Current	$1.6B	$1.4B	$1.4B	$1.5B	$1.6B
Cash and Cash Equivalents, at Carrying Value	$91.5M	$26.0M	$247.8M	$341.4M	$151.2M
Accounts Receivable, after Allowance for Credit Loss, Current	—	—	—	$662.6M	$638.9M
Inventory, Net	$612.5M	$581.4M	$530.7M	$489.4M	$490.6M
Liabilities	—	—	—	—	—
Liabilities, Current	$1.1B	$846.6M	$752.8M	$677.2M	$676.9M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	$345.6M	$65.1M	$241.8M	$379.0M	$1.7M
Net Cash Provided by (Used in) Investing Activities	-$69.2M	-$174.3M	-$194.2M	-$317.5M	-$19.6M
Net Cash Provided by (Used in) Financing Activities	-$212.6M	-$106.6M	-$138.1M	$131.8M	-$45.8M
Payments to Acquire Property, Plant, and Equipment	$43.2M	$46.4M	$47.7M	$56.4M	$47.2M
Payments of Dividends	—	—	—	—	—
Payments for Repurchase of Equity	—	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)